The pharma firms allege that Watson is violating numerous patents with its proposed generic version of the testosterone gel.
Auxilium Pharmaceuticals, Inc. and FCB I LLC announced today that they filed a lawsuit against Watson Laboratories, Inc.; Watson Pharmaceuticals, Inc.; and Watson Pharma, Inc. (collectively, "Watson") for infringement of FCB's ten patents listed in the U.S. Food and Drug Administration's ("FDA's") Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book") as covering Testim 1% testosterone gel. The lawsuit was filed in the United States District Court for the District of New Jersey on May 23, 2012.
